Quick answers
- What is Triazolam used for?
- The FDA-approved label (Triazolam, Mylan Pharmaceuticals Inc., July 10, 2026) says: “Triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. Triazolam is a benzodiazepine indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Triazolam have a boxed warning?
- Yes. The FDA label for Triazolam has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Triazolam?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Triazolam been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Triazolam?
- 9 companies list prescription products of Triazolam in the FDA NDC Directory, including A-S Medication Solutions, Zydus Lifesciences Limited and Zydus Pharmaceuticals USA Inc..
What Triazolam is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. Triazolam is a benzodiazepine indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults.
— FDA label: Triazolam, Mylan Pharmaceuticals Inc., effective July 10, 2026. Read the full label on DailyMed →
The FDA has 10 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
9 of 10 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 14 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| triazolam 0.125 mg tablet | Generic | $0.2799 per tablet |
| triazolam 0.25 mg tablet | Generic | $0.3325 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- A-S Medication Solutions2 products
- Zydus Lifesciences Limited2 products
- Zydus Pharmaceuticals USA Inc.2 products
- Ingenus Pharmaceuticals, LLC2 products
- Mylan Pharmaceuticals Inc.2 products
- PD-Rx Pharmaceuticals, Inc.1 product
- Proficient Rx LP1 product
- Bryant Ranch Prepack1 product
- Aphena Pharma Solutions - Tennessee, LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA017892 HALCION | Pfizer | November 15, 1982 | 39, latest January 13, 2023 2023: Labeling · 2021: Labeling · 2021: Labeling |
Generic approvals (2)
- ANDA214219Ingenus Pharms LLC · October 20, 2020
- ANDA213003Zydus Pharms · December 28, 2022
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 198317, 198318 |
|---|---|
| SPL set ID of the quoted label | 5add318e-11b9-42f8-b052-0d8cebb32fcf |
| FDA labels (SPL) | 10 |
| FDA applications | NDA017892, 2 ANDA |
| Active ingredients (FDA) | TRIAZOLAM |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Triazolam, Mylan Pharmaceuticals Inc., effective July 10, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →